CoChat

A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial

Open access

The DOI matches its Crossref record; 155 of the 160 references it cites were found in a registry or an index.

Abstract

Background: Insulin is generally administered to people with type 1 diabetes mellitus (T1DM) using multiple daily injections (MDIs), but can also be delivered using infusion pumps. In the UK, pumps are recommended for patients with the greatest need and adult use is less than in comparable countries. Previous trials have been small, of short duration and have failed to control for training in insulin adjustment. Objective: To assess the clinical effectiveness and cost-effectiveness of pump therapy compared with MDI for adults with T1DM, with both groups receiving equivalent structured training in flexible insulin therapy. Design: Pragmatic, multicentre, open-label, parallel-group cluster randomised controlled trial, including economic and psychosocial evaluations. After participants were assigned a group training course, courses were randomly allocated in pairs to either pump or MDI. Setting: Eight secondary care diabetes centres in the UK. Participants: Adults with T1DM for > 12 months, willing to undertake intensive insulin therapy, with no preference for pump or MDI, or a clinical indication for pumps. Interventions: Pump or MDI structured training in flexible insulin therapy, followed up for 2 years. MDI participants used insulin analogues. Pump participants used a Medtronic Paradigm®Veo TM(Medtronic, Watford, UK) with insulin aspart (NovoRapid, Novo Nordisk, Gatwick, UK). Main outcome measures: Primary outcome – change in glycated haemoglobin (HbA 1c) at 2 years in participants whose baseline HbA 1c was ≥ 7.5% (58 mmol/mol). Key secondary outcome – proportion of participants with HbA 1c≤ 7.5% at 2 years. Other outcomes at 6, 12 and 24 months – moderate and severe hypoglycaemia; insulin dose; body weight; proteinuria; diabetic ketoacidosis; quality of life (QoL); fear of hypoglycaemia; treatment satisfaction; emotional well-being; qualitative interviews with participants and staff (2 weeks), and participants (6 months); and ICERs in trial and modelled estimates of cost-effectiveness. Results: We randomised 46 courses comprising 317 participants: 267 attended a Dose Adjustment For Normal Eating course (132 pump; 135 MDI); 260 were included in the intention-to-treat analysis, of which 235 (119 pump; 116 MDI) had baseline HbA 1c of ≥ 7.5%. HbA 1c and severe hypoglycaemia improved in both groups. The drop in HbA 1c% at 2 years was 0.85 on pump and 0.42 on MDI. The mean difference (MD) in HbA 1c change at 2 years, at which the baseline HbA 1c was ≥ 7.5%, was –0.24% [95% confidence interval (CI) –0.53% to 0.05%] in favour of the pump (p = 0.098). The per-protocol analysis showed a MD in change of –0.36% (95% CI –0.64% to –0.07%) favouring pumps (p = 0.015). Pumps were not cost-effective in the base case and all of the sensitivity analyses. The pump group had greater improvement in diabetes-specific QoL diet restrictions, daily hassle plus treatment satisfaction, statistically significant at 12 and 24 months and supported by qualitative interviews. Limitation: Blinding of pump therapy was not possible, although an objective primary outcome was used. Conclusion: Adding pump therapy to structured training in flexible insulin therapy did not significantly enhance glycaemic control or psychosocial outcomes in adults with T1DM. Research priority: To understand why few patients achieve a HbA 1c of < 7.5%, particularly as glycaemic control is worse in the UK than in other European countries. Trial registration: Current Controlled Trials ISRCTN61215213. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 20. See the NIHR Journals Library website for further project information.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta21200

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 155 references

Research works printed but not linked: 24

  1. NICE, 2008, Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus
  2. NICE, 2013, Guide to the Methods of Technology Appraisal 2013
  3. Ray, 2013, Dose adjustment for normal eating (DAFNE) structured education reduces progression to continuous subcutaneous insulin infusion (CSII) among patients being considered for insulin pump therapy at enrolment, Diabet Med, 30, 7
  4. Nosadini, 1988, Frequency of hypoglycaemic and hyperglycaemic-ketotic episodes during conventional and subcutaneous continuous insulin infusion therapy in IDDM, Diabetes Nutr Metab Clin Exp, 1, 289
  5. Bacon, 2014, The effectiveness and safety of continuous subcutaneous insulin infusion in a large adult cohort over a 10 year period, Ir J Med Sci, 1, S450
  6. NICE, 2016, Integrated sensor-dugmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system)
  7. Zijlstra, 2015, Faster-acting insulin aspart by continuous subcutaneous insulin infusion: earlier exposure and greater early pharmacokinetic/pharmacodynamic effects vs. insulin aspart, Diabetologia, 1, S452
  8. Medical Research Council/DH/MHRA Joint Project, 2011, Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products
  9. Curtis, 2014, Unit Costs of Health and Social Care 2014
  10. DAFNE, 2012, DAFNE Fact Sheet Six
  11. Department of Health, 2014, NHS Reference Costs 2013 to 2014
  12. Department of Health, 2013, NHS Reference Costs 2012 to 2013
  13. Joint Formulary Committee, British National Formulary (online)
  14. Health and Social Care Information Centre, 2015, Prescription Cost Analysis England 2014
  15. London New Drugs Group, 2013, Comparative Table of Insulin Pumps
  16. Palmer JL. Cost-effectiveness of Angiotensin-converting Enzyme Inhibitors for the Prevention of Cardiovascular and End-stage Renal Disease in Patients with Type 1 Diabetes. 2012. PhD thesis. Sheffield: University of Sheffield; 2012.
  17. Joint Formulary Committee, 2012, British National Formulary
  18. Department of Health, 2011, NHS Reference Costs 2010–11
  19. The WHOQOL Group, 1996, WHOQOL-Bref: Introduction, Administration, Scoring and Generic Version of the Assessment
  20. Office for National Statistics, 2010, Standard occupational classification 2010
  21. Scottish Government, 2012, Scottish Index of Multiple Deprivation 2012
  22. NICE, Type 1 Diabetes in Adults: Diagnosis and Management
  23. Health and Social Care Information Centre, 2014, National Diabetes Audit 2012–13. Report 1: Care Processes and Treatment Targets
  24. SIGN, 2013, Management of Diabetes: A National Clinical Guideline

Cited by

Metadata

Authors
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., Campbell, M., Cooper, C., Dimairo, M., Dixon, S., Elliott, J., Evans, M., Green, F., Hackney, G., Hammond, P., Hallowell, N., Jaap, A., Kennon, B., Kirkham, J., Lindsay, R., Mansell, P., Papaioannou, D., Rankin, D., Royle, P., Smithson, W. H., & Taylor, C.
Affiliations
  • University of Sheffield (GB)
  • University of Edinburgh (GB)
  • University of Warwick (GB)
  • King's College London (GB)
  • University of Southampton (GB)
  • King's College Hospital NHS Foundation Trust (GB)
  • Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK
  • University of Cambridge (GB)
  • Dumfries and Galloway Royal Infirmary (GB)
  • Harrogate and District NHS Foundation Trust (GB)
  • Edinburgh Royal Infirmary (GB)
  • NHS Greater Glasgow and Clyde (GB)
  • University of Glasgow (GB)
  • Nottingham University Hospitals NHS Trust (GB)
  • University College Cork (IE)
  • Sheffield Teaching Hospitals NHS Foundation Trust (GB)
Corresponding author
Heller, Simon
Venue
Health Technology Assessment
Published
2017-04
Volume
21
Issue
20
Pages
1-278
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
OpenAlex
W2607776465
Cited by
73
References
160
Citations by year
2026: 1 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 13 · 2020: 10 · 2019: 9 · 2018: 12 · 2017: 4
FWCI
7.56
Type
journal article
Language
en
Open access
Locations
  • Health Technology Assessment (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • Arrow@dit (Dublin Institute of Technology) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Portal (King's College London) (submittedVersion, other-oa)
  • Cork Open Research Archive (University College Cork, Ireland) (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
Health Technology Assessment programme (08/107/01)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 1 diabetes, insulin pump therapy, multiple daily insulin injections, HbA1c, hypoglycemia, cost-effectiveness, quality of life, fear of hypoglycemia, insulin aspart, insulin analogues, diabetes self-management education, emotional well-being
MeSH terms
Adolescent, Adult, Aged, Blood Glucose, Body Weight, Cost-Benefit Analysis, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Female, United Kingdom, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Middle Aged, Proteinuria, Quality of Life, State Medicine, Technology Assessment, Biomedical, Diabetic Ketoacidosis, Quality-Adjusted Life Years, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.